Why Big Pharma Is Writing Checks
Health care dealmaking accelerated sharply in the first quarter of 2026, and we believe the structural forces behind that activity are still in early innings. Large pharmaceutical companies are facing a pipeline problem that cannot be solved organically: patent expirations on blockbuster franchises will eliminate tens of billions in annual revenue over the next five years, and internal R&D timelines cannot close that gap. The result is an acquisition environment that is, in our view, unusually favorable for biopharma assets with established commercial franchises, the part of the health care market where we have concentrated our highest-conviction exposure.
The Urgency Is Real
The patent cliff problem is not new. What has changed is the urgency. A significant portion of large pharmaceutical revenue sits in franchises facing generic entry before the end of the decade, and the math is unforgiving: when a single drug generates billions in annual revenue and loses exclusivity, a company cannot grow its way through the gap organically. It needs to acquire.
The catalyst was the resolution of uncertainty around pharmaceutical reimbursement reform, a policy overhang that had effectively frozen dealmaking for much of the prior two years. As that uncertainty resolved, large pharma moved with speed. In our view, Q1 2026 produced one of the highest M&A hit rates in health care equities we have observed across the companies we follow. In several cases, multiple acquirers were competing for the same asset simultaneously, a signal that the strategic imperative is no longer optional.
2026 is on pace to set a record for the number of $1 billion-plus biopharma acquisitions in a single year, nearly doubling the prior record set in 2025.
Source: S&P, CapitalIQ, and Stifel Investment Banking Research.
Three Forces Converging
The urgency to act does not explain why the current environment is producing deals at elevated premiums. Three additional conditions have aligned to make this a particularly active window.
First, the regulatory posture has become more predictable. The antitrust overhang that had deterred large strategic combinations in prior periods has meaningfully receded, giving acquirers more confidence to engage in competitive processes and move with decisiveness.
Second, development-stage biotech valuations remain well below their 2021 peak. After two years of multiple compression, many commercial-stage and late-stage clinical companies are trading at multiples that make strategic acquisition feasible rather than prohibitive. Acquirers are not being asked to pay peak-cycle prices for assets they need. The window is open.
Third, the cost of capital has stabilized. Higher rates over the prior two years created balance sheet discipline. As the rate environment has normalized, large-cap pharmaceutical companies are redeploying accumulated cash and accessing debt at costs that make acquisitions accretive on a reasonable time horizon.
The top 26 pharmaceutical companies hold an estimated $1.4 trillion in combined M&A firepower, providing the capital runway to sustain elevated deal activity through this cycle.
Comfortable firepower defined as capacity to a net debt/EBITDA ratio of 3x; stretch firepower defined as capacity to 5x. Source: S&P CapitalIQ, Stifel Investment Banking Department Analysis.
What Acquirers Are Actually Buying
Not all biotech is equally attractive to acquirers, and a substantial portion of the development-stage universe will not attract strategic interest at any reasonable price. In our experience, the most durable acquisition targets share a small number of characteristics.
They have de-risked the science. The most compelling targets are companies with validated mechanisms: commercial-stage or late-stage clinical assets where the biology has been proven and the acquirer is paying for certainty rather than optionality. The deals getting done today are not bets on preclinical programs. They are acquisitions of assets where the hard work is finished and the commercial trajectory is visible.
They possess something the acquirer cannot replicate. The best targets have a structural advantage (a proprietary delivery platform, a validated patient population with longitudinal outcome data, a manufacturing capability) that would take an acquirer years to build from scratch. If the acquirer can recreate the asset internally within three to five years, they will try. The companies that attract meaningful premiums are the ones where that calculus does not work.
They offer runway, not maturity. Acquirers want to buy into upside, not peak revenue. The most attractive targets have either just launched a commercial product or have major near-term catalysts remaining. Entering a franchise in years two through five of a decade-long commercial cycle is far more valuable to a strategic buyer than acquiring a mature asset already past peak.
Our Positioning
We have been deliberately constructive in this environment. Our highest-conviction exposure in health care is concentrated in commercial-stage biopharma: companies with differentiated franchises, meaningful near-term clinical catalysts, and characteristics that make them strategically valuable to large pharmaceutical acquirers. We do not build positions around acquisition speculation; each name has to work as a standalone investment. But we believe that owning the right assets in the right part of the market means that M&A outcomes represent additional upside, not the thesis itself.
In our view, the structural conditions supporting biopharma consolidation (patent-driven urgency, compressed valuations, improved regulatory predictability, and available capital) remain firmly in place. We enter the second half of 2026 with our highest level of conviction in health care in several years, and we believe the portfolio is well positioned to participate as this cycle continues to develop.
This material is for informational purposes only and should not be construed as investment advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. All investments involve risk, including loss of principal. Westfield Capital Management Company, L.P. is a registered investment adviser.
The software sector is facing its most fundamental repricing in over two decades. Unlike prior corrections where concerns, today's fear is structural obsolescence. The market isn't asking "how much slower will they grow?” it's asking, "will they exist?"
2025 marked the fifth consecutive year the median Mid Cap Growth manager underperformed the benchmark. The message is clear: being average in Mid Cap Growth is not good enough. Today’s Mid Cap Growth benchmark demands a comprehensive approach.
On our 3Q webcast, we highlighted several areas that made the market feel increasingly vulnerable: narrow leadership, heavy retail participation, and speculative pockets that had gone parabolic. Over the past few weeks, many of the issues have begun to surface.
Fear and rhetoric have weighed heavily on Health Care equities, but we believe this has created a compelling entry point. With valuations at multi-year lows, pipelines maturing, and secular drivers intact, the sector is, in our view, positioned for a multi-year recovery.
Subscribe to Westfield Insights.
*Indicates required field
By subscribing you agree to our Privacy Policy and electronic marketing communications.
